Literature DB >> 10665755

Vincristine (Vinca-alkaloid) as a sclerosing agent for malignant pleural effusions.

M S Vidyasagar1, A S Ramanujam, D J Fernandes, K Koteshwar Rao, G K Jadhav, C S Hospet, T Seetharamaiah, S Vidyasagar, K Subramanyam.   

Abstract

Vincristine, extracted from Vinca rosea Linn., is an effective antineoplastic chemotherapeutic drug used in oncology practice. This drug has never been used as a sclerosing agent for the treatment of malignant pleural effusion for reasons unknown. A study was conducted to examine the use of Vinca-Alkaloid as a sclerosing agent (pleurodesis) for the palliative treatment of malignant pleural effusions. The study included 15 patients, all diagnosed to have cytology-proven malignant pleural effusions. Intercostal tube drainage followed by chemical sclerotherapy with 2 mg vincristine was performed on all patients and a high success rate was noted. Twelve procedures out of 15 (12/15) achieved complete resolution of pleural fluid with a success rate of 80%. In two procedures the pleural effusion was reduced and then recurred but did not require re-aspiration. One procedure failed and repeated pleural aspiration was required. In this study, with adequate pleural drainage and the proper technique, vincristine was found to be an effective sclerosing agent for malignant pleural effusion. Further randomized trials are necessary in order to establish the role of this drug.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10665755     DOI: 10.1080/028418699432284

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  2 in total

1.  Unusual thoracic manifestation of metastatic malignant melanoma.

Authors:  K Manu Mohan; K Gowrinath
Journal:  Lung India       Date:  2010-04

2.  Polyphenol-rich Avicennia marina leaf extracts induce apoptosis in human breast and liver cancer cells and in a nude mouse xenograft model.

Authors:  Cheng Huang; Chung-Kuang Lu; Ming-Chin Tu; Jia-Hua Chang; Yen-Ju Chen; Yu-Hsuan Tu; Hsiu-Chen Huang
Journal:  Oncotarget       Date:  2016-06-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.